Mouse Anti-Human VEGFR1-14/Flt1-14 (peptide), soluble
Slide this table
| Cat-Nr. | 101-M29 |
| Size | 100 µg |
| Price | 275 € |
| Category | Monoclonal Antibody |
| Clone Nr. | (#180F3B4) |
| Isotype | IgG1 |
| Species Reactivity | Human |
| Formulation | lyophilized |
| Buffer | PBS |
| Reconstitution | Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml. |
| Stability and Storage | The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots. |
| Antigen | uniquie C terminal peptide of sFlt1-14 |
| Application | ELISA, WB, IHC |
| Synonyms | vascular endothelial growth factor receptor-1; FLT1; VEGF receptor 1 |
| Description | A human-specific splicing variant of vascular endothelial growth factor (VEGF) receptor 1 (Flt1) was discovered, producing a soluble receptor (designated sFlt1-14) that is qualitatively different from the previously described soluble receptor (sFlt1) and functioning as a potent VEGF inhibitor. sFlt1-14 is generated in a cell type-specific fashion, primarily in non-endothelial cells. Notably, in vascular smooth muscle cells, all Flt1 messenger RNA is converted to sFlt1-14, whereas endothelial cells of the same human vessel express sFlt1. sFlt1-14 expression by vascular smooth muscle cells is dynamically regulated as evidenced by its upregulation on coculture with endothelial cells or by direct exposure to VEGF. Increased production of soluble VEGF receptors during pregnancy is entirely attributable to induced expression of placental sFlt1-14 starting by the end of the first trimester. Expression is dramatically elevated in the placenta of women with preeclampsia, specifically induced in abnormal clusters of degenerative syncytiotrophoblasts known as syncytial knots, where it may undergo further messenger RNA editing. sFlt1-14 is the predominant VEGF-inhibiting protein produced by the preeclamptic placenta, accumulates in the circulation, and hence is capable of neutralizing VEGF in distant organs affected in preeclampsia. Together, these findings revealed a new natural VEGF inhibitor that has evolved in humans, possibly to protect non-endothelial cells from adverse VEGF signaling. Furthermore, the study uncovered the identity of a VEGF-blocking protein implicated in preeclampsia. |
| Uniprot ID | P17948-3 |
| Protein RefSeq | NP_001153502.1 |
| mRNA RefSeq | NM_001160030.1 |
Figures
Immunofluorescence staining (green) of cryo-sections of human foreskin with mouse anti-human sFlt1-14 antibody [Cat# 101-M29] and counter staining of nuclei with Dapi (blue). (B) Control; Fixation: 4% PFA (app. 25min); Dilution: 1:500. Staining in smooth muscle cells, the perineurium of nerves and the Stratum basale of the epidermis as well as some scattered cells.
The experiment was performed by the research group of Prof. Dr. J. Wilting and M. Lohrberg, University Göttingen, Germany.
Western Blot Analysis of recombinant human sFlt-1(D5) [Cat# S01-012], sFlt-1 [Cat# S01-010], sFlt1-14 [Cat# S01-072], sKDR(D7) [Cat# S01-002] and sFLT-4 [Cat# S01-018] using a monoclonal mouse anti-human sFlt1-14 antibody [Cat# 101-M29] generated against a peptide from the unique C terminal end (left panel) and a monoclonal mouse anti-human Flt-1 [Cat# 101-M30] recognizing all Flt-1 proteins used as control (right panel).
Immunoperoxidase staining of paraffin-embedded sections of human foreskin with mouse anti-human sFlt1-14 antibody. (D) Control; Fixation: 4% PFA (app. 25min); Dilution: 1:100-500. The staining in smooth muscle cells is visible.
The experiment was performed by the research group of Prof. Dr. J. Wilting and M. Lohrberg, University Göttingen, Germany.
Direct ELISA: recombinant human sFlt-1(D5) [Cat# S01-012], sFlt-1 [Cat# S01-010] and sFlt1-14 [Cat# S01-072] were coated with 1µg/ml in PBS. The sFlt1-14 specific mouse anti-human sFlt1-14 antibody generated against a peptide from the unique C terminal end [Cat# 101-M29] was used with 2µg/ml, the Flt-1 specific mouse anti-human Flt-1 #EWI [Cat# 101-M30] recognizing all Flt-1 proteins was used as control [1µg/ml].
All prices plus VAT + possible delivery charges